Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Vico Therapeutics logo — Our mission is simple… bring innovative RNA modulating thera...

Vico Therapeutics

Our mission is simple… bring innovative RNA modulating therapies to patients with severe, genetic neurological diseases.

Founded 2019 The Netherlands The Netherlands 49 employees Series B Total: $108.30M Health Care, Pharmaceutical

General Information

Company Name Vico Therapeutics
Founded Year 2019
Location The Netherlands The Netherlands
Founders / Decision Makers
Team member
Employees 49
Industries Health Care, Pharmaceutical
Funding Stage Series B
Business Model B2B, B2B2B
Revenue Model Product Sales, Licensing, Performance Based
Social

BounceWatch is an independent company data service, not affiliated with Vico Therapeutics. To contact Vico Therapeutics, visit vicotx.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Vico Therapeutics compare?

A PDF of Vico Therapeutics and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Vico Therapeutics soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Vico Therapeutics

Vico Therapeutics is making strides in the Health Care and Pharmaceutical industries by focusing on innovative RNA modulating therapies for severe genetic neurological diseases. Founded in 2019 and based in The Netherlands, the company aims to address conditions like spinocerebellar ataxia types 3 and 1, and Huntington’s disease.

Their proprietary VICOMER platform designs antisense oligonucleotides that can modulate or edit RNA, promising targeted therapeutic benefits. This groundbreaking technology holds potential as a significant advancement in treating genetic neurological disorders.

In its latest funding round, Vico Therapeutics secured a €11.50M Series B investment on June 24, 2024. The round was led by notable investors including Kurma Partners, Polaris Partners, Ackermans & van Haaren, Euazeo, Seroba Life Sciences, Droia Ventures, Pureos Bioventures, and EQT Life Sciences, signaling strong confidence and support in their vision and approach.

Business keywords: RNA Modulating Therapies, Genetic Neurological Diseases, Spinocerebellar Ataxia Type 3, Spinocerebellar Ataxia Type 1, Huntington’s Disease, Antisense Oligonucleotides, CNS Disorders, Rare Neurological Disorders, Ribonucleic Acid Therapies, Hereditary Ataxia, Neurodegenerative Disorders, Neurodevelopmental Disorders, VICOMER Platform, Rett Syndrome

Services & Products

Development of Antisense Oligonucleotide Therapies
Clinical Trials for Genetic Disorders
Genetic Intervention Research

Target Customers

Patients with Rare Neurological Diseases Caregivers Advocacy Communities Healthcare Providers specializing in Neurology

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Series B €11.50M 8
Kurma Partners Polaris Partners Ackermans & van Haaren
Kurma Partners, Polaris Partners +6
24 Jun 2024
Series B €65.80M 2
Euazeo
Euazeo, Pureos Bioventures
05 Jan 2024
Series A $31.00M -
29 Jul 2020

Vico Therapeutics Alternatives & Competitors

View All Alternatives
Vico Therapeutics vs
Dyne Therapeutics
Dyne Therapeutics United States

Advancing life-transforming therapies for serious muscle diseases

Post-IPO Equity
292 employees
Biotechnology, Health Care
Compare Vico Therapeutics vs Dyne Therapeutics
Vico Therapeutics vs
Praxis Precision Medicines, Inc.
Praxis Precision Medicines, Inc. United States

The era of genetic neuroscience has arrived

IPO
244 employees
Biotechnology, Health Care
Compare Vico Therapeutics vs Praxis Precision Medicines, Inc.
Vico Therapeutics vs
Nuvamid
Nuvamid Switzerland

A clinical stage biotech focused on the research and use of nucleotides, as therapeutics for rare di...

4 employees
Health Care, Manufacturing
View all alternatives

FAQ About Vico Therapeutics

Our mission is simple… bring innovative RNA modulating therapies to patients with severe, genetic neurological diseases.
Vico Therapeutics was founded in 2019.
Vico Therapeutics is headquartered in The Netherlands.
Vico Therapeutics operates in Health Care and Pharmaceutical. Its work centres on RNA Modulating Therapies, Genetic Neurological Diseases, Spinocerebellar Ataxia Type 3 and Spinocerebellar Ataxia Type 1. Its customers include Patients with Rare Neurological Diseases, Caregivers and Advocacy Communities.
Vico Therapeutics has a B2B and B2B2B business model. Its revenue comes from Product Sales, Licensing and Performance Based.
Vico Therapeutics has approximately 49 employees.
Vico Therapeutics has completed 3 funding rounds, raising a total of $108.30M. The latest funding stage is Series B.
Vico Therapeutics offers: Development of Antisense Oligonucleotide Therapies, Clinical Trials for Genetic Disorders, Genetic Intervention Research.
Top alternatives and competitors to Vico Therapeutics include Dyne Therapeutics, Praxis Precision Medicines, Inc., Nuvamid, Ultragenyx, Dynacure. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Vico Therapeutics and Dyne Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Vico Therapeutics, https://bouncewatch.com/company/vico-therapeutics, updated 7 September 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout